Eminence Biotechnology Co., Ltd. reported that its state-of-the-art facility for the commercial production of cell culture media is fully operational. The opening aims to address the rapidly growing demand for high-quality media in the fields of vaccines, gene therapies, cell therapies, antibodies, and recombinant proteins.

The new facility, at the BIOBAY Phase II, Suzhou Industrial Park, occupies approximately 7,000 square meters and comprises dedicated zones for media production, warehousing, and laboratory functions. With three dry powder production lines and two liquid production lines, the facility has an annual output of up to 20 million liters of dry powder media and 300,000 liters of liquid media.

The new facility adheres to international GMP standards, ISO9001, and ISO13485 regulations. It is designed to provide biopharmaceutical companies worldwide with consistently high-quality, batch-to-batch stable cell culture media products.

Frank Song, Chairman and CEO of Eminence, said, “From the very beginning, our focus has been firmly set on the field of cell culture media. After over seven years of growth, our factory in Changzhou has reached its capacity, and this new facility was designed leveraging the operational experience from Changzhou and integrating it with more advanced large-scale pin-milling technology to standardize production processes, ensuring stable and continuous production.”